常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.62/-2.54
|
|
企业价值
16.23M
|
| 资产负债 |
|
每股账面净值
-1.14
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
7.88M
|
|
每股收益
0.79
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/16 04:41 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |

1.33 
